23 June 2021 
Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, has raised CHF 2.6m from private investors. The proceeds will be used to continue the preclinical and clinical develop of its lead molecules for prostate cancer, neuroendocrine tumours, and immunotherapy selection. Swiss Nuclides is developing the PET tracers on a novel radionuclide production platform which enables the broad availability of these tracers while keeping the radiation burden on the patient to a minimum.
VISCHER AG has been assisting Swiss Nuclides in this financing, the team is led by Dr. Matthias Staehelin with Dania Salvisberg.
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]